ArticleClinical medicine (London, England)2026
Frailty phenotype, genetic risk and long-term incident systemic lupus erythematosus risk: Insights from the UK Biobank study integrated with multi-omics analysis.
Article in Clinical medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty, a marker of biological ageing and reduced physiological reserve, is linked to many chronic conditions, yet its role in the development of systemic lupus erythematosus (SLE) remains unclear.
aimsTo examine the association between frailty and incident SLE and to investigate potential inflammatory and genetic mechanisms underlying this relationship.
methodsWe conducted a prospective cohort study among 462,762 participants from the UK Biobank to examine the associations of physical frailty and frailty index with incident SLE. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals, with further analyses assessing the interaction and joint effects of frailty and polygenic risk. Gene-level overlap between frailty and SLE was evaluated using MAGMA. In addition, we integrated circulating inflammatory markers and plasma proteomic profiles to identify potential mediating pathways and candidate biomarkers.
resultsDuring a median follow-up of 13.2 years, 309 of 462,762 participants (0.07%) developed incident SLE. Compared to non-frail individuals, both pre-frail and frail participants had a higher risk of developing SLE, with stronger associations observed in those with higher polygenic risk scores. Gene analysis identified 39 shared genes that were significantly correlated with both frailty and SLE. Circulating inflammatory markers, including C-reactive protein, were found to partially mediate the frailty-SLE relationship. Proteomic analyses identified ANGPTL3, CST3 and TNFSF8 as the candidate risk-related biomarkers associated with future incident SLE.
conclusionFrailty is associated with an increased long-term risk of incident SLE, particularly in genetically susceptible individuals. Inflammatory cell measures and circulating proteins, including ANGPTL3, CST3 and TNFSF8, may help identify elevated SLE risk in pre-frail and frail populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.